Drug intelligence / Profile preview

atorvastatin + telmisartan

Development stage
Phase 1
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral
01

Overview

Atorvastatin + telmisartan is a fixed-dose combination drug used to treat patients with both high blood pressure (hypertension) and high cholesterol (dyslipidemia). Atorvastatin is a statin that inhibits HMG-CoA reductase to reduce cholesterol synthesis in the liver and lower LDL cholesterol and triglycerides while raising HDL cholesterol. Telmisartan is an angiotensin II receptor blocker (ARB) that blocks the action of angiotensin II on vascular smooth muscle and adrenal gland AT1 receptors. This leads to vasodilation and reduced blood pressure. The combination lowers cardiovascular risk by addressing two major risk factors—hypertension and hypercholesterolemia—simultaneously[1][4]. Clinical studies show this combination improves lipid profiles and blood pressure control in patients with comorbid conditions such as obesity or non-alcoholic fatty liver disease[4].

Brand names
Arbitel-AVTeleact StTelsartan AtrLipisarTemsan CVUrvistat-TPleotor TTesarto-ACreslip
Other names
telmisartan + atorvastatin
02

Targets

AGTR1 (Angiotensin II Type-1 receptor)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)PPARG (Peroxisome proliferator-activated receptor gamma)

Beyond the preview

Go deeper on atorvastatin + telmisartan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on atorvastatin + telmisartan.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call